@article{Allegretti:2020:10.1053/j.gastro.2020.07.045,
author = {Allegretti, JR and Kelly, CR and Grinspan, A and Mullish, BH and Kassam, Z and Fischer, M},
doi = {10.1053/j.gastro.2020.07.045},
journal = {Gastroenterology},
pages = {1982--1984},
title = {Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection},
url = {http://dx.doi.org/10.1053/j.gastro.2020.07.045},
volume = {159},
year = {2020}
}

Download

TY  - JOUR
AB  - There has been an increase in the burden of Clostridioides difficile infection (CDI),1 especially in high-risk populations such as patients with inflammatory bowel disease (IBD).2 The prevalence of CDI in the IBD population is up to 8-fold higher than comparable controls, with increased rates of recurrence and CDI-associated mortality.3 In addition, CDI may induce an IBD flare, and worsen disease severity and clinical course.4Fecal microbiota transplantation (FMT) is a guideline recommended therapy for recurrent CDI5; however, supportive randomized trials excluded patients with IBD. In retrospective trials of patients with IBD, FMT failure rates had been reported to be approximately 25% to 30%.6 In addition, Khoruts and colleagues reported that patients with IBD and CDI were more likely to fail FMT,7 leading to further uncertainty regarding the safety and efficacy of FMT in IBD patients with concurrent CDI. Accordingly, we conducted the first prospective study examining the efficacy of FMT among patients with IBD and CDI.MethodsWe conducted an open-label, prospective, single-arm, multicenter cohort study at 4 tertiary care FMT referral centers (Brigham and Women’s Hospital, Indiana University, Brown University, and Mount Sinai Hospital; NCT03106844). Patients with a confirmed diagnosis of IBD and 2 or more confirmed CDI episodes within 12 months, including the most recent episode occurring within 3 months, were enrolled. In keeping with CDI clinical guidelines,5 polymerase chain reaction or glutamate dehydrogenase with toxin enzyme immunoassay were permitted for the qualifying CDI episode. Patients with a total or subtotal colectomy, isolated ileal or small bowel Crohn’s disease, those pregnant or breastfeeding, those treated with vancomycin or metronidazole for more than 60 days, or those who had undergone a prior FMT within 12 months were excluded. Baseline IBD and CDI data were collected. All patients underwent a single FMT via colonoscopy. Four robus
AU  - Allegretti,JR
AU  - Kelly,CR
AU  - Grinspan,A
AU  - Mullish,BH
AU  - Kassam,Z
AU  - Fischer,M
DO  - 10.1053/j.gastro.2020.07.045
EP  - 1984
PY  - 2020///
SN  - 0016-5085
SP  - 1982
TI  - Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection
T2  - Gastroenterology
UR  - http://dx.doi.org/10.1053/j.gastro.2020.07.045
UR  - https://www.sciencedirect.com/science/article/pii/S0016508520350083?via%3Dihub
VL  - 159
ER  - 

Download